352 related articles for article (PubMed ID: 26113085)
1. Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice.
Sanmamed MF; Rodriguez I; Schalper KA; Oñate C; Azpilikueta A; Rodriguez-Ruiz ME; Morales-Kastresana A; Labiano S; Pérez-Gracia JL; Martín-Algarra S; Alfaro C; Mazzolini G; Sarno F; Hidalgo M; Korman AJ; Jure-Kunkel M; Melero I
Cancer Res; 2015 Sep; 75(17):3466-78. PubMed ID: 26113085
[TBL] [Abstract][Full Text] [Related]
2. Induction of lethal graft-versus-host disease by anti-CD137 monoclonal antibody in mice prone to chronic graft-versus-host disease.
Kim W; Kim J; Jung D; Kim H; Choi HJ; Cho HR; Kwon B
Biol Blood Marrow Transplant; 2009 Mar; 15(3):306-14. PubMed ID: 19203721
[TBL] [Abstract][Full Text] [Related]
3. Histological assessment of the sclerotic graft-versus-host response in the humanized RAG2-/-γc-/- mouse model.
Hogenes MC; van Dorp S; van Kuik J; Monteiro FR; ter Hoeve N; van Dijk MR; Martens AC; de Weger RA
Biol Blood Marrow Transplant; 2012 Jul; 18(7):1023-35. PubMed ID: 22579931
[TBL] [Abstract][Full Text] [Related]
4. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
[TBL] [Abstract][Full Text] [Related]
5. Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies.
Azpilikueta A; Agorreta J; Labiano S; Pérez-Gracia JL; Sánchez-Paulete AR; Aznar MA; Ajona D; Gil-Bazo I; Larrayoz M; Teijeira A; Rodriguez-Ruiz ME; Pio R; Montuenga LM; Melero I
J Thorac Oncol; 2016 Apr; 11(4):524-36. PubMed ID: 26845193
[TBL] [Abstract][Full Text] [Related]
6. Human regulatory T cells control xenogeneic graft-versus-host disease induced by autologous T cells in RAG2-/-gammac-/- immunodeficient mice.
Mutis T; van Rijn RS; Simonetti ER; Aarts-Riemens T; Emmelot ME; van Bloois L; Martens A; Verdonck LF; Ebeling SB
Clin Cancer Res; 2006 Sep; 12(18):5520-5. PubMed ID: 17000688
[TBL] [Abstract][Full Text] [Related]
7. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates.
Wang C; Thudium KB; Han M; Wang XT; Huang H; Feingersh D; Garcia C; Wu Y; Kuhne M; Srinivasan M; Singh S; Wong S; Garner N; Leblanc H; Bunch RT; Blanset D; Selby MJ; Korman AJ
Cancer Immunol Res; 2014 Sep; 2(9):846-56. PubMed ID: 24872026
[TBL] [Abstract][Full Text] [Related]
8. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
Ito A; Ishida T; Utsunomiya A; Sato F; Mori F; Yano H; Inagaki A; Suzuki S; Takino H; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
J Immunol; 2009 Oct; 183(7):4782-91. PubMed ID: 19748990
[TBL] [Abstract][Full Text] [Related]
9. T cell costimulation with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes.
Martinez-Forero I; Azpilikueta A; Bolaños-Mateo E; Nistal-Villan E; Palazon A; Teijeira A; Perez-Chacon G; Morales-Kastresana A; Murillo O; Jure-Kunkel M; Zapata JM; Melero I
J Immunol; 2013 Jun; 190(12):6694-706. PubMed ID: 23690480
[TBL] [Abstract][Full Text] [Related]
10. Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes.
Palazón A; Teijeira A; Martínez-Forero I; Hervás-Stubbs S; Roncal C; Peñuelas I; Dubrot J; Morales-Kastresana A; Pérez-Gracia JL; Ochoa MC; Ochoa-Callejero L; Martínez A; Luque A; Dinchuk J; Rouzaut A; Jure-Kunkel M; Melero I
Cancer Res; 2011 Feb; 71(3):801-11. PubMed ID: 21266358
[TBL] [Abstract][Full Text] [Related]
11. Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor.
Shindo Y; Yoshimura K; Kuramasu A; Watanabe Y; Ito H; Kondo T; Oga A; Ito H; Yoshino S; Hazama S; Tamada K; Yagita H; Oka M
Anticancer Res; 2015 Jan; 35(1):129-36. PubMed ID: 25550543
[TBL] [Abstract][Full Text] [Related]
12. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
[TBL] [Abstract][Full Text] [Related]
13. A model of human anti-T-cell monoclonal antibody therapy in SCID mice engrafted with human peripheral blood lymphocytes.
Tsuchida M; Brown SA; Tutt LM; Tan J; Seehafer DL; Harris JP; Xun CQ; Thompson JS
Clin Transplant; 1997 Oct; 11(5 Pt 2):522-8. PubMed ID: 9361954
[TBL] [Abstract][Full Text] [Related]
14. Engraftment and activity of anti-CD3-activated human peripheral blood lymphocytes transferred into mice with severe combined immune deficiency.
Murphy WJ; Conlon KC; Sayers TJ; Wiltrout RH; Back TC; Ortaldo JR; Longo DL
J Immunol; 1993 Apr; 150(8 Pt 1):3634-42. PubMed ID: 8468492
[TBL] [Abstract][Full Text] [Related]
15. Human monocyte-derived suppressor cells control graft-versus-host disease by inducing regulatory forkhead box protein 3-positive CD8+ T lymphocytes.
Janikashvili N; Trad M; Gautheron A; Samson M; Lamarthée B; Bonnefoy F; Lemaire-Ewing S; Ciudad M; Rekhviashvili K; Seaphanh F; Gaugler B; Perruche S; Bateman A; Martin L; Audia S; Saas P; Larmonier N; Bonnotte B
J Allergy Clin Immunol; 2015 Jun; 135(6):1614-24.e4. PubMed ID: 25630940
[TBL] [Abstract][Full Text] [Related]
16. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
17. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies.
Ascierto PA; Simeone E; Sznol M; Fu YX; Melero I
Semin Oncol; 2010 Oct; 37(5):508-16. PubMed ID: 21074066
[TBL] [Abstract][Full Text] [Related]
18. Host CD25+CD4+Foxp3+ regulatory T cells primed by anti-CD137 mAbs inhibit graft-versus-host disease.
Kim J; Kim W; Kim HJ; Park S; Kim HA; Jung D; Choi HJ; Park SJ; Mittler RS; Cho HR; Kwon B
Biol Blood Marrow Transplant; 2012 Jan; 18(1):44-54. PubMed ID: 21958951
[TBL] [Abstract][Full Text] [Related]
19. Comparison of three humanized mouse models for adoptive T cell transfer.
Volk A; Hartmann S; Muik A; Geiss Y; Königs C; Dietrich U; von Laer D; Kimpel J
J Gene Med; 2012 Aug; 14(8):540-8. PubMed ID: 22847974
[TBL] [Abstract][Full Text] [Related]
20. Anti-class II -DR humanized monoclonal antibody, IMMU-114, blocks allogeneic immune response.
Park KH; Sawada T; Murakami T; Ishii Y; Yasuo M; Fuchinoue S; Goldenberg DM; Kubota K
Am J Surg; 2012 Oct; 204(4):527-34. PubMed ID: 22658578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]